Picture loading failed.

Pre-made Vedolizumab benchmark antibody (Whole mAb, anti-ITGA4;ITGB7 therapeutic antibody, Anti-CD49D/IA4 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc (currently named Takeda Oncology, a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name Entyvio.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-616-1mg 1mg 3090
GMP-Bios-ab-616-10mg 10mg Inquiry
GMP-Bios-ab-616-100mg 100mg Inquiry
GMP-Bios-ab-616-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vedolizumab biosimilar, Whole mAb, Anti-ITGA4;ITGB7 Antibody: Anti-CD49D/IA4 therapeutic antibody
INN Name Vedolizumab
TargetITGA4_ITGB7
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesMedical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology
Conditions ApprovedCrohn's disease;Ulcerative colitis
Conditions ActiveGraft-versus-host disease;Coeliac disease
Conditions DiscontinuedMalignant melanoma
Development Techna